FDA Reauthorization Act of 2017

H.R. 2430 · 115th Congress · Aug 18, 2017 · Lineage

AN ACT

To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.

Section 1 Short title

This Act may be cited as the “FDA Reauthorization Act of 2017”.

Sec. 2 Table of contents

The table of contents for this Act is as follows:

Lineage

Aug 18, 2017 Pub. L. 115–52 Enacted
Aug 18, 2017viewing Enrolled Bill See what changed
Jul 13, 2017 Placed on Calendar Senate Received; read the first time See what changed
Jul 12, 2017 Engrossed in House See what changed
May 16, 2017 Reported in House Mr. Walden (for himself, Mr. Pallone, Mr. Burgess, and Mr. Gene Green of Texas) introduced the following bill; which was referred to the Committee on Energy and Commerce See what changed
May 16, 2017 Introduced in House Mr. Walden (for himself, Mr. Pallone, Mr. Burgess, and Mr. Gene Green of Texas) introduced the following bill; which was referred to the Committee on Energy and Commerce

FDA Reauthorization Act of 2017

Section 1 Short title

Sec. 2 Table of contents

Cite this provision

Incoming references